Zimmer Biomet (NYSE:ZBH) Stock Price Expected to Rise, Citigroup Analyst Says

Zimmer Biomet (NYSE:ZBH) had its price target increased by investment analysts at Citigroup from $94.00 to $98.00 in a note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage currently has a “neutral” rating on the medical equipment provider’s stock. Citigroup’s target price indicates a potential upside of 3.01% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price target for the company from $94.00 to $120.00 in a report on Monday, January 5th. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a report on Wednesday, November 5th. BTIG Research restated a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a research note on Tuesday. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Price Performance

Shares of ZBH opened at $95.14 on Wednesday. The company has a market capitalization of $18.85 billion, a price-to-earnings ratio of 26.87, a P/E/G ratio of 2.71 and a beta of 0.62. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.39. The business’s 50-day moving average is $90.05 and its 200-day moving average is $95.64.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period last year, the company posted $2.31 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares during the last quarter. Dodge & Cox grew its holdings in Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after purchasing an additional 1,118,710 shares during the last quarter. Capital International Investors raised its position in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after purchasing an additional 778,467 shares during the period. Franklin Resources Inc. lifted its stake in shares of Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after buying an additional 2,017,857 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after buying an additional 458,903 shares during the period. 88.89% of the stock is owned by institutional investors.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback — ZBH topped estimates on revenue and EPS, and the company announced a new buyback that pushed the stock higher after results. Positive near-term cash-return and sales momentum were highlighted. Article Title
• Positive Sentiment: Buy-side upgrade — BTIG Research issued a “Buy” on ZBH, supporting upside sentiment among some investors. Article Title
• Positive Sentiment: Index inclusion/lift — Coverage noted ZBH’s results helped lift the Russell 1000 Healthcare index, signaling industry-level recognition of the quarter. Article Title
• Neutral Sentiment: Analyst price-target moves — Citigroup and Wells Fargo raised ZBH price targets to $98 while keeping neutral/equal-weight ratings, which signals modest upside but not a broad bullish repositioning. Article Title
• Neutral Sentiment: Hold reaffirmation — Needham reaffirmed a “Hold” on ZBH, reflecting mixed analyst conviction despite the beat. Article Title
• Neutral Sentiment: Sector context — A MarketBeat piece comparing healthcare earnings highlights peers (e.g., AstraZeneca) outperforming in profit growth, which provides cross-checks for relative performance but is not company-specific. Article Title
• Negative Sentiment: Guidance caution from salesforce changes — Deep-dive coverage flagged a U.S. salesforce overhaul that prompted management to strike a measured tone on FY26 guidance, introducing execution risk that likely weighs on the stock today. Article Title
• Negative Sentiment: Measured tone on guidance in the earnings call — Transcripts and coverage emphasize that while Q4 beat, management set cautious FY26 commentary and guidance range, which may limit investor upside until execution is clearer. Article Title

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.